Actively Recruiting
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
Led by Jinling Hospital, China · Updated on 2026-04-23
20
Participants Needed
2
Research Sites
18 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.
CONDITIONS
Official Title
Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants voluntarily provided written informed consent for this trial
- Aged 18 to 80 years, inclusive, regardless of gender
- With stable vital signs
- Diagnosis of SBS-IF, confirmed by existing medical or surgical records
- Receiving parenteral nutrition due to surgical resection of the small intestine (less than 200 cm from the duodenojejunal flexure)
- Colon continuity maintained without jejunal or ileal stoma (Type II or III) or presence of a jejunostomy or ileostomy (Type I)
- Expected requirement of parenteral nutrition for more than 4 weeks with an average PN caloric intake of 80% or more
- Ability to comply with medication dosing and visit schedule
- Capacity to accurately describe symptoms, absence of severe infections or respiratory insufficiency, and willingness to cooperate proactively
- No history of allergic diseases, non-allergic constitution, and no hypersensitivity to any component of semaglutide injection
- No history of drug abuse
- Not pregnant or lactating; no pregnancy plans within one month after the trial (applies to both female and male participants)
- No participation in any other drug trials within three months prior to enrollment
You will not qualify if you...
- Individuals who do not meet the inclusion criteria or are deemed ineligible by the investigator
- Poor general condition, inability to accurately describe symptoms, presence of severe infection, respiratory insufficiency, or other conditions that may hinder active cooperation
- History of allergic diseases, allergic constitution, or hypersensitivity to drugs structurally related to the investigational product
- Patients with malignancy at any site
- Those with psychiatric disorders, inability to cooperate, or impaired consciousness
- Patients with contraindications to the investigational drug, including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2
- Immunodeficiency, or current use of immunosuppressants or corticosteroids
- Immediate family members of the sponsor, investigator, or study staff directly involved in the trial
- Any other condition considered by the investigator as grounds for exclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Jinling Hospital
Nanjing, China, China, 210002
Actively Recruiting
2
Jinling Hospital
Nanning, China, China, 210002
Actively Recruiting
Research Team
X
Xin Qi, MD
CONTACT
X
Xinying Wang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here